Sheridan: Yes, it’s a very segmented market. There are people out there that want different use cases, they want different control mechanisms, they want different wear choices. It’s not going to be an entirely tubeless market going forward. There is just going to be a lot of variety in terms of what people want. We believe one product is not going to solve all the needs of the various segments of diabetes. We need to have multiple products and that’s what we’re going to provide.

We have a portfolio approach. We have different sensor integrations. We have different software. We have different algorithms. All this provides choice for people so that when they come to Tandem, they can find what they want and what fits their particular needs when it comes to managing their bodies. The innovation will really become the simplification of the interaction with the system. So it will be the way you control the pump. We have an algorithm on a system that controls the amount of insulin. Every five minutes it decides whether you need additional insulin or whether you need less insulin and makes that decision for you. The algorithms immediately reduce the cognitive burden of managing diabetes because it makes these decisions for you.

There are other things that we can also do to simplify the experience that people have. There are other algorithms that we can have at the interface that can simplify managing meals. For instance, as opposed to having to enter the amount of carbohydrates you ate, we have algorithms that can help that process and simplify it. We also have algorithms that can look at the settings you're using to measure diabetes, and it can determine whether or not they're optimized. If they are not optimized, we will optimize them for you.

What are the biggest differentiators between the Tandem pump and your competitors?

Exec Chat: Tandem CEO Sheridan On Coming Mobi Pump, New Algorithms, And Taking Share From Medtronic

“Our strategy is like Nordstrom – we want to provide ‘White Glove’ service to people.”

More from Digital Technologies

More from Medtech Insight